Evaluation of Device Settings for Airway Clearance Using The Monarch Airway Clearance System
NCT ID: NCT03645473
Last Updated: 2018-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
10 participants
INTERVENTIONAL
2019-01-24
2019-04-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective:
Assess device settings and to identify frequency/pressure (intensity) combinations that produce high airflow and oscillating volume
Methodology:
Subjects will receive HFCWO using The Monarch® System at multiple frequency / intensity combinations on a single visit day. Frequency / intensity combinations will be evaluated to determine which settings produce highest airflow and highest oscillating volume.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will evaluate oscillating airflow and oscillating volume induced during therapy with the Monarch® system. Subjects will also rate the comfort of the therapy. Patients with cystic fibrosis (CF) who meet all of the inclusion criteria and none of the exclusion criteria will be enrolled in the study.
Therapy with the Monarch® system will be delivered using multiple frequency/intensity combination settings. The order of settings will be randomized for each study subject. During therapy oscillating flow and volume measurements will be obtained for each frequency/intensity combination. Following each frequency/intensity combination, subjects will respond to a subjective assessment of the comfort of the therapy by rating the comfort on a visual analogue scale (VAS).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DEVICE_FEASIBILITY
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Monarch device settings assessment group
Patients with cystic fibrosis who have experience with the Monarch Airway Clearance System will be enrolled in the study.
The duration of subject participation is approximately 4 - 6 hours during 1 study visit. Each subject will receive therapy with The Monarch® System at multiple frequency and intensity combinations as defined in the Study procedures.
Monarch Airway Clearance System
HFCWO Airway Clearance Device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Monarch Airway Clearance System
HFCWO Airway Clearance Device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 15 years
* Require regular home airway clearance therapy
* Current user of The Monarch® System with a minimum of 4 weeks experience with the device
* Signed informed consent. If patient is a minor, parents/guardians must give written informed consent and patient must give written assent
* Patient must be on a stable regimen of CF medication
Exclusion Criteria
* History of hemoptysis requiring embolization within the past 12 months prior to study visit or hemoptysis of \> 100 ml within a 24-hour period within the past 30 days
* History of lobectomy
* Recent chest surgery or chest trauma
* Inability to perform The Monarch® System therapy as directed
* Pregnant or lactating female
* Have a pacemaker or implantable cardioverter defibrillator (ICD)
* Requirement for oral or IV antibiotics that are not part of the subject's usual course of treatment within the past 14 days prior to screening
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hill-Rom
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR-RR-2018-002
Identifier Type: -
Identifier Source: org_study_id